drugset / Trial / NCT00304616

SWitching to Abilify Trial (SWAT)

NCT00304616

Phase 4 Completed 500 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration

Timeline

Start
2004-10
Primary completion
2006-06
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg Oral
Subject Aripiprazole Other / unclassified 30 mg Oral
Background Amisulpride Small molecule
Background Olanzapine Small molecule
Background Quetiapine Small molecule
Background Risperidone Other / unclassified

Indications